We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.055 | -2.52% | 2.125 | 2.05 | 2.20 | 2.25 | 2.10 | 2.20 | 2,365,381 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.89 | 7.17M |
Date | Subject | Author | Discuss |
---|---|---|---|
08/1/2018 13:47 | sometimes I get the impression this bb is run by only one person with 20 different personalities XD. Very low risk for me here. People be patient. | jpleight | |
08/1/2018 13:42 | Alliance news? Your broker said LOOOOOOOOL. WHAT DOES THAT EXACTLY MEAN | john09 | |
08/1/2018 13:41 | Gap in charts filled at 170p too.... | flavio_monteiro | |
08/1/2018 13:40 | Alliance news my broker said | nw99 | |
08/1/2018 13:34 | Yes. NW99. He lied to Posters on FLX and FOOT boards recently too. I police his ass | john09 | |
08/1/2018 13:32 | Can’t see 150p again, I would try and top up but World and his mistress will be frantically buying. This pull back to 170 ish seems reasonable for those not yet holding or anyone that fancies adding a few more. Whoever was posting about the Panmure sell to 100p should be investigated by IMM, their brokers & Adfvn as its spreading blatantly false information, they should be prosecuted, that was when the shares were 38p, it was a buy rec to 150p | ny boy | |
08/1/2018 13:25 | Walter Mitty time and time and time again don’t know how you sleep at night | john09 | |
08/1/2018 13:25 | We are waiting | john09 | |
08/1/2018 13:25 | So “they” “told you” and also provided something you could cut and paste lol Humour me. How did your clarification go? | john09 | |
08/1/2018 13:21 | Ask them also where you got your cut and paste from you goon | john09 | |
08/1/2018 13:20 | Yes you ask “them” now and “clarify” | john09 | |
08/1/2018 13:20 | Yes NW99 Who is your broker? And if they “told” you about it why instead are you cutting and pasting stuff ! | john09 | |
08/1/2018 13:20 | I am asking them now to clarify it | nw99 | |
08/1/2018 13:18 | Out of interest, who is your broker?Given the FCA rules they have to abide by, it would be interesting for them to explain the supposed sell rating that Panmure have given....I dare say Panmure might not be too happy about it either. | sportbilly1976 | |
08/1/2018 13:16 | If that's what you are getting as 'information' and investment assistance from your broker, I suggest looking for a new one. | sportbilly1976 | |
08/1/2018 13:14 | Thanks waterloo | luminoso | |
08/1/2018 13:14 | I’ve told you, ignore the vermin. NW99. He will post eroneous BS to suit himself | john09 | |
08/1/2018 13:13 | Vadim Alexandre (Northland Capital) IMM Presentation 4/7/2017 34 min 45 sec: "HGSi's takeout price was $3.6 billion for 50% of the rights (to Benlysta)... so we can assume roughly Benlysta was bought for $7 billion...and that's in 2012...so if we are looking at a drug (Lupuzor) that could be better, the price could be higher...a novel treatment in lupus could command that price...because it already has... ...and then just in terms of pricing for the drug...Tim mentioned $20k per patient per year, that's not very expensive...Benlysta is commanding $35k per patient per year...(I am even more conservative in my model) if we have a drug that is as good or better (Lupuzor)...$40k, $50k per patient per year isn't unachievable... ...the regulatory position speaks miles...a SPA and Fast Track designation...the FDA dosn't dole these out lightly...the regulator is behind this drug... ...if the trial is successful we are going to see a re-rating of the stock price...the types of deals that are closed are not small deals...you could expect an upfront payment to dwarf the market capitalisation of the company...P140 is now being shown to affect other diseases with major indications ...rheumatoid arthritis, asthma, Crohns, the list goes on and on, so a potential buyer, even 'though lupus is big enough, won't just buy it for lupus it will buy it for all these other indications as well...I definately think this stock is currently undervalued..." Q&A Q: What value do analysts apply to Nucant and Urelix? A: "Zero, because...the valution for Lupus (Lupuzor) is so high, so its almost pointless to talk about it...If they were to be seperated in a sum of parts, they do have value but the lead asset is worth so much more... But you are right, the Urelix platform is very interesting a company like Novo would be very interested in that. Nucant...very good data...if it were to be valued standalone, would be worth a substantial amount of the currrent market capitalisation". | hottingup | |
08/1/2018 13:12 | There is no new note from Panmure. They are quoting the note from Jan 2017. The last note was Finncap. | waterloo01 | |
08/1/2018 13:12 | Has anyone actually given Panmure a call? They could easily affirm/dismiss the claim within a couple of minutes. | sportbilly1976 | |
08/1/2018 13:11 | Could you ask your broker for confirmation of where they got it from, in case it is a mistake ? It seems like a rehash of a year old target to me. | luminoso | |
08/1/2018 13:10 | I would expect this to be updated, if there is any truth in it. | luminoso |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions